Design an AI-enabled software as a medical device that offers cutting-edge capabilities and earns the trust of healthcare professionals, ultimately improving patient care.
Back to team page
Andrew Zawisza
Quality Director
Andrew has 10 years of experience in the medical device industry in various roles within quality assurance and regulatory affairs. During this time, he led preparation efforts for a successful first-time FDA inspection, research efforts to support 510(k) submissions, and investigation and resolution of product and process deficiencies. He also implemented statistical methods and lean tools to improve process efficiency. This experience has provided him with a unique perspective on how a quality system can be an effective tool for any company. At Bold Insight, Andrew is responsible for the development and maintenance of our quality system, ensuring the continuous improvement of our processes and the quality of service we provide our clients. Andrew holds an BS in Bioengineering from Michigan State University.



Bold facts
Learn more about

Something unique about you summed up in one sentence:

Your favorite part of working at Bold Insight:

In your spare time (or if you had spare time), you would absolutely do this:

How long have you been in the UX field?

Your favorite city in the world is...and why?

Your ultimate celebrity dinner party guest list would include:

Long-term personal or professional goal?

Any other facts to share?
Read our team’s latest bold insights
Why UX people make great strategy consultants
Learn why UX researchers excel as strategy consultants through data-driven approaches that address critical decisions and adapt to new contexts.
Global UX, mastered: The UXalliance’s 20-year collaboration story
This year marks the 20th anniversary of the UXalliance. To celebrate this milestone, we sat down with Gavin, one of the five founding members, to discuss the organization’s history, guiding principles, and the benefits it brings to clients.
Human factors testing for OTC drugs and non-prescription medical devices
As the field of human factors continues to evolve, so must our approaches to testing and study design. While the FDA’s 2013 guidance laid the groundwork for study design and methodology, recent discussions and conference presentations have prompted a shift in how we approach OTC HF testing, leading to more comprehensive and realistic assessments of these products.